AMRX
Amneal Pharmaceuticals, Inc.
Price Chart
Latest Quote
$14.19
Current Price| Previous Close | $13.68 |
| Open | $13.65 |
| Day High | $14.29 |
| Day Low | $13.64 |
| Volume | 2,902,762 |
Stock Information
| Shares Outstanding | 314.36M |
| Total Debt | $2.69B |
| Cash Equivalents | $203.48M |
| Revenue | $2.93B |
| Net Income | $5.90M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $4.46B |
| P/E Ratio | 1419.00 |
| EPS (TTM) | $0.01 |
| Exchange | NMS |
📊 Custom Metrics & Score
Score: 14/42| Debt to Equity | -23.73 |
| Debt to Earnings | 2.54 |
| Current Ratio | 1.41 |
| Quick Ratio | 0.81 |
| Avg Revenue Growth | 8.36% |
| Profit Margin | -4.18% |
| Return on Equity | 106.97% |
| Avg FCF Growth | 4.09% |
| FCF Yield | 4.93% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $14.19 | 2,912,500 |
| 2026-01-30 | $13.68 | 4,462,000 |
| 2026-01-29 | $14.11 | 33,034,200 |
| 2026-01-28 | $13.95 | 9,386,000 |
| 2026-01-27 | $13.83 | 2,232,600 |
| 2026-01-26 | $13.57 | 1,099,500 |
| 2026-01-23 | $13.39 | 864,100 |
| 2026-01-22 | $13.58 | 898,800 |
| 2026-01-21 | $13.71 | 1,323,600 |
| 2026-01-20 | $13.33 | 1,103,000 |
| 2026-01-16 | $13.41 | 2,253,700 |
| 2026-01-15 | $13.19 | 1,328,400 |
| 2026-01-14 | $13.25 | 1,561,800 |
| 2026-01-13 | $12.97 | 2,218,700 |
| 2026-01-12 | $12.98 | 1,507,400 |
| 2026-01-09 | $12.96 | 1,511,600 |
| 2026-01-08 | $13.20 | 1,220,000 |
| 2026-01-07 | $13.26 | 1,515,100 |
| 2026-01-06 | $12.99 | 1,500,400 |
| 2026-01-05 | $12.71 | 1,726,400 |
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
📰 Latest News
3 Cash-Producing Stocks That Concern Us
StockStory • 2026-02-02T04:40:41Z
Is It Too Late To Consider Amneal Pharmaceuticals (AMRX) After Its Strong Multi‑Year Share Price Run?
Simply Wall St. • 2026-01-30T17:11:26Z
Opioid Settlement And Index Inclusion Reframe Amneal Pharmaceuticals Risk And Reach
Simply Wall St. • 2026-01-30T09:15:38Z
3 Healthcare Stocks We Steer Clear Of
StockStory • 2026-01-30T04:34:20Z
Will Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?
Zacks • 2026-01-28T17:10:03Z
2 Reasons to Sell AMRX and 1 Stock to Buy Instead
StockStory • 2026-01-26T04:02:48Z
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year?
Zacks • 2026-01-22T14:40:02Z
3 Growth Companies With High Insider Ownership And Up To 79% Earnings Growth
Simply Wall St. • 2026-01-19T11:35:57Z
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Zacks • 2026-01-15T14:40:04Z
Amneal Pharmaceuticals Eyes 2026 Growth at JPMorgan, Crexont Sales Seen Doubling in 2025
MarketBeat • 2026-01-14T02:04:44Z
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Reconciled Cost Of Revenue | $1,773,519,000 | $1,573,042,000 | $1,427,596,000 | $1,324,696,000 |
| Cost Of Revenue | $1,773,519,000 | $1,573,042,000 | $1,427,596,000 | $1,324,696,000 |
| Total Revenue | $2,793,957,000 | $2,393,607,000 | $2,212,304,000 | $2,093,669,000 |
| Operating Revenue | $2,793,957,000 | $2,393,607,000 | $2,212,304,000 | $2,093,669,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $258,595,000 | $210,629,000 | $158,377,000 | $136,325,000 |
| Total Expenses | $2,446,514,000 | $2,169,357,000 | $2,023,382,000 | $1,899,763,000 |
| Other Income Expense | $-143,861,000 | $-13,086,000 | $-278,381,000 | $-26,215,000 |
| Other Non Operating Income Expenses | $11,782,000 | $8,243,000 | $18,464,000 | $15,330,000 |
| Net Non Operating Interest Income Expense | $-258,595,000 | $-251,434,000 | $-158,668,000 | $-136,325,000 |
| Interest Expense Non Operating | $258,595,000 | $210,629,000 | $158,377,000 | $136,325,000 |
| Operating Expense | $672,995,000 | $596,315,000 | $595,786,000 | $575,067,000 |
| Total Other Finance Cost | - | $40,805,000 | $291,000 | - |
| Other Operating Expenses | - | $-1,138,000 | $-3,960,000 | - |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-116,886,000 | $-83,993,000 | $-129,986,000 | $10,624,000 |
| Net Interest Income | $-258,595,000 | $-251,434,000 | $-158,668,000 | $-136,325,000 |
| Normalized Income | $6,071,970 | $-67,143,090 | $104,521,550 | $37,337,435 |
| Net Income From Continuing And Discontinued Operation | $-116,886,000 | $-83,993,000 | $-129,986,000 | $10,624,000 |
| Total Operating Income As Reported | $249,326,000 | $204,374,000 | $-94,928,000 | $152,716,000 |
| Net Income Common Stockholders | $-116,886,000 | $-83,993,000 | $-129,986,000 | $10,624,000 |
| Net Income | $-116,886,000 | $-83,993,000 | $-129,986,000 | $10,624,000 |
| Net Income Including Noncontrolling Interests | $-73,876,000 | $-48,722,000 | $-254,789,000 | $20,170,000 |
| Net Income Continuous Operations | $-73,876,000 | $-48,722,000 | $-254,789,000 | $20,170,000 |
| Pretax Income | $-55,013,000 | $-40,270,000 | $-248,127,000 | $31,366,000 |
| Special Income Charges | $-148,797,000 | $-23,000,000 | $-284,481,000 | $-41,190,000 |
| Operating Income | $347,443,000 | $224,250,000 | $188,922,000 | $193,906,000 |
| Gross Profit | $1,020,438,000 | $820,565,000 | $784,708,000 | $768,973,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.38 | $-0.48 | $-0.86 | $0.07 |
| Basic EPS | $-0.38 | $-0.48 | $-0.86 | $0.07 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-32,685,030 | $-4,479,090 | $-62,337,450 | $-14,831,565 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $595,416,000 | $421,088,000 | $447,270,000 | $442,642,000 |
| Total Unusual Items | $-155,643,000 | $-21,329,000 | $-296,845,000 | $-41,545,000 |
| Total Unusual Items Excluding Goodwill | $-155,643,000 | $-21,329,000 | $-296,845,000 | $-41,545,000 |
| Reconciled Depreciation | $236,191,000 | $229,400,000 | $240,175,000 | $233,406,000 |
| EBITDA (Bullshit earnings) | $439,773,000 | $399,759,000 | $150,425,000 | $401,097,000 |
| EBIT | $203,582,000 | $170,359,000 | $-89,750,000 | $167,691,000 |
| Diluted Average Shares | $308,978,000 | $176,136,000 | $150,944,000 | $151,821,000 |
| Basic Average Shares | $308,978,000 | $176,136,000 | $150,944,000 | $148,922,000 |
| Diluted NI Availto Com Stockholders | $-116,886,000 | $-83,993,000 | $-129,986,000 | $10,624,000 |
| Minority Interests | $-43,010,000 | $-35,271,000 | $124,803,000 | $-9,546,000 |
| Tax Provision | $18,863,000 | $8,452,000 | $6,662,000 | $11,196,000 |
| Other Special Charges | $147,372,000 | $35,748,000 | $281,620,000 | $31,078,000 |
| Restructuring And Mergern Acquisition | $1,425,000 | $-12,748,000 | $2,861,000 | $10,112,000 |
| Gain On Sale Of Security | $-6,846,000 | $1,671,000 | $-12,364,000 | $-355,000 |
| Other Taxes | $50,680,000 | $3,124,000 | $631,000 | - |
| Research And Development | $196,559,000 | $167,778,000 | $200,046,000 | $209,563,000 |
| Selling General And Administration | $476,436,000 | $429,675,000 | $399,700,000 | $365,504,000 |
| Gain On Sale Of Business | - | - | $0 | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-1,439,080,000 | $-1,469,271,000 | $-1,396,525,000 | $-1,399,599,000 |
| Total Assets | $3,501,445,000 | $3,472,569,000 | $3,799,341,000 | $3,939,664,000 |
| Total Non Current Assets | $1,913,639,000 | $2,094,706,000 | $2,387,523,000 | $2,419,556,000 |
| Other Non Current Assets | $5,278,000 | $7,126,000 | $8,191,000 | $9,220,000 |
| Non Current Prepaid Assets | $16,114,000 | $6,875,000 | $7,234,000 | $9,791,000 |
| Non Current Deferred Assets | $2,820,000 | $4,427,000 | $2,206,000 | $1,603,000 |
| Financial Assets | $35,921,000 | $37,089,000 | $85,586,000 | $0 |
| Goodwill And Other Intangible Assets | $1,329,813,000 | $1,489,052,000 | $1,694,946,000 | $1,759,939,000 |
| Other Intangible Assets | $732,377,000 | $890,423,000 | $1,096,093,000 | $1,166,922,000 |
| Current Assets | $1,587,806,000 | $1,377,863,000 | $1,411,818,000 | $1,520,108,000 |
| Restricted Cash | $7,868,000 | $7,565,000 | $9,251,000 | $41,949,000 |
| Prepaid Assets | $48,368,000 | $51,712,000 | $48,946,000 | $46,240,000 |
| Inventory | $612,454,000 | $581,384,000 | $530,735,000 | $489,389,000 |
| Receivables | $808,564,000 | $645,660,000 | $796,910,000 | $694,740,000 |
| Other Receivables | $15,520,000 | $17,805,000 | $41,738,000 | $22,128,000 |
| Taxes Receivable | $16,829,000 | $13,168,000 | $12,881,000 | $8,850,000 |
| Accounts Receivable | $775,731,000 | $613,732,000 | $741,791,000 | $662,583,000 |
| Allowance For Doubtful Accounts Receivable | $-528,057,000 | $-586,248,000 | $-603,168,000 | $-529,209,000 |
| Gross Accounts Receivable | $1,303,788,000 | $1,199,980,000 | $1,344,959,000 | $1,191,792,000 |
| Cash Cash Equivalents And Short Term Investments | $110,552,000 | $91,542,000 | $25,976,000 | $247,790,000 |
| Cash And Cash Equivalents | $110,552,000 | $91,542,000 | $25,976,000 | $247,790,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Debt | $2,375,451,000 | $2,549,034,000 | $2,695,672,000 | $2,500,915,000 |
| Total Debt | $2,593,139,000 | $2,750,523,000 | $2,845,135,000 | $2,876,056,000 |
| Long Term Debt And Capital Lease Obligation | $2,252,884,000 | $2,522,899,000 | $2,740,496,000 | $2,830,019,000 |
| Long Term Debt | $2,161,790,000 | $2,427,451,000 | $2,631,687,000 | $2,718,091,000 |
| Current Debt And Capital Lease Obligation | $340,255,000 | $227,624,000 | $104,639,000 | $46,037,000 |
| Current Debt | $324,213,000 | $213,125,000 | $89,961,000 | $30,614,000 |
| Other Current Borrowings | $224,213,000 | $34,125,000 | $29,961,000 | $30,614,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $3,610,957,000 | $3,452,558,000 | $3,615,362,000 | $3,572,691,000 |
| Total Non Current Liabilities Net Minority Interest | $2,481,186,000 | $2,605,963,000 | $2,862,562,000 | $2,895,448,000 |
| Other Non Current Liabilities | $94,051,000 | $8,215,000 | $70,168,000 | $2,664,000 |
| Tradeand Other Payables Non Current | $1,252,000 | $497,000 | $563,000 | $3,177,000 |
| Current Liabilities | $1,129,771,000 | $846,595,000 | $752,800,000 | $677,243,000 |
| Other Current Liabilities | $31,755,000 | $76,988,000 | $107,483,000 | $58,000,000 |
| Payables And Accrued Expenses | $684,802,000 | $470,861,000 | $486,640,000 | $511,108,000 |
| Payables | $291,228,000 | $161,119,000 | $178,685,000 | $191,694,000 |
| Other Payable | $10,226,000 | $10,226,000 | $10,226,000 | $10,226,000 |
| Accounts Payable | $258,691,000 | $143,572,000 | $165,980,000 | $131,084,000 |
| Derivative Product Liabilities | - | - | $0 | $11,473,000 |
| Total Tax Payable | - | - | $359,000 | $2,523,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $-109,267,000 | $19,781,000 | $298,421,000 | $360,340,000 |
| Total Equity Gross Minority Interest | $-109,512,000 | $20,011,000 | $183,979,000 | $366,973,000 |
| Stockholders Equity | $-109,267,000 | $19,781,000 | $298,421,000 | $360,340,000 |
| Gains Losses Not Affecting Retained Earnings | $-65,510,000 | $-32,349,000 | $9,939,000 | $-24,827,000 |
| Other Equity Adjustments | $-65,510,000 | $-32,349,000 | $9,939,000 | $-24,827,000 |
| Retained Earnings | $-607,062,000 | $-490,176,000 | $-406,183,000 | $-276,197,000 |
| Preferred Securities Outside Stock Equity | $64,974,000 | $41,293,000 | $24,949,000 | $16,907,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $309,881,000 | $306,565,000 | $151,490,000 | $149,413,000 |
| Share Issued | $309,881,000 | $306,565,000 | $151,490,000 | $149,413,000 |
| Tangible Book Value | $-1,439,080,000 | $-1,469,271,000 | $-1,396,525,000 | $-1,399,599,000 |
| Invested Capital | $2,376,736,000 | $2,660,357,000 | $3,020,069,000 | $3,109,045,000 |
| Working Capital | $458,035,000 | $531,268,000 | $659,018,000 | $842,865,000 |
| Capital Lease Obligations | $107,136,000 | $109,947,000 | $123,487,000 | $127,351,000 |
| Total Capitalization | $2,052,523,000 | $2,447,232,000 | $2,930,108,000 | $3,078,431,000 |
| Minority Interest | $-245,000 | $230,000 | $-114,442,000 | $6,633,000 |
| Additional Paid In Capital | $560,206,000 | $539,240,000 | $691,629,000 | $658,350,000 |
| Capital Stock | $3,099,000 | $3,066,000 | $3,036,000 | $3,014,000 |
| Common Stock | $3,099,000 | $3,066,000 | $3,036,000 | $3,014,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $17,125,000 | $21,283,000 | $16,737,000 | $21,589,000 |
| Dueto Related Parties Non Current | $50,900,000 | $11,776,000 | $9,649,000 | $9,619,000 |
| Long Term Capital Lease Obligation | $91,094,000 | $95,448,000 | $108,809,000 | $111,928,000 |
| Current Capital Lease Obligation | $16,042,000 | $14,499,000 | $14,678,000 | $15,423,000 |
| Line Of Credit | $100,000,000 | $179,000,000 | $60,000,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $72,959,000 | $71,122,000 | $54,038,000 | $62,098,000 |
| Current Accrued Expenses | $393,574,000 | $309,742,000 | $307,955,000 | $319,414,000 |
| Dueto Related Parties Current | $22,311,000 | $7,321,000 | $2,479,000 | $47,861,000 |
| Goodwill | $597,436,000 | $598,629,000 | $598,853,000 | $593,017,000 |
| Net PPE | $523,693,000 | $550,137,000 | $589,360,000 | $639,003,000 |
| Accumulated Depreciation | $-563,520,000 | $-508,027,000 | $-445,971,000 | $-394,562,000 |
| Gross PPE | $1,087,213,000 | $1,058,164,000 | $1,035,331,000 | $1,033,565,000 |
| Leases | $130,905,000 | $126,461,000 | $124,668,000 | $123,508,000 |
| Construction In Progress | $78,198,000 | $67,665,000 | $69,344,000 | $58,263,000 |
| Other Properties | $98,785,000 | $102,563,000 | $119,545,000 | $124,845,000 |
| Machinery Furniture Equipment | $546,558,000 | $524,614,000 | $485,438,000 | $484,415,000 |
| Buildings And Improvements | $224,655,000 | $227,837,000 | $225,630,000 | $230,994,000 |
| Land And Improvements | $8,112,000 | $9,024,000 | $10,706,000 | $11,540,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $351,922,000 | $304,077,000 | $247,606,000 | $227,079,000 |
| Work In Process | $52,835,000 | $59,563,000 | $58,522,000 | $47,802,000 |
| Raw Materials | $207,697,000 | $217,744,000 | $224,607,000 | $214,508,000 |
| Duefrom Related Parties Current | $484,000 | $955,000 | $500,000 | $1,179,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $220,109,000 | $276,388,000 | $-25,495,000 | $189,181,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $295,099,000 | $345,577,000 | $65,100,000 | $241,820,000 |
| Cash Flow From Continuing Operating Activities | $295,099,000 | $345,577,000 | $65,100,000 | $241,820,000 |
| Operating Gains Losses | $7,191,000 | $-768,000 | $15,190,000 | $175,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-74,990,000 | $-69,189,000 | $-90,595,000 | $-52,639,000 |
| Investing Cash Flow | $-62,996,000 | $-69,189,000 | $-174,309,000 | $-194,182,000 |
| Cash Flow From Continuing Investing Activities | $-62,996,000 | $-69,189,000 | $-174,309,000 | $-194,182,000 |
| Net Other Investing Changes | - | - | $1,000,000 | $5,000,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $-211,791,000 | $-212,573,000 | $-106,620,000 | $-138,122,000 |
| Cash Flow From Continuing Financing Activities | $-211,791,000 | $-212,573,000 | $-106,620,000 | $-138,122,000 |
| Net Other Financing Charges | $-27,827,000 | $-235,676,000 | $-69,010,000 | $-59,796,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-233,118,000 | $-414,080,000 | $-123,272,000 | $-79,179,000 |
| Issuance Of Debt | $48,000,000 | $436,732,000 | $85,000,000 | $0 |
| Interest Paid Supplemental Data | $263,518,000 | $192,806,000 | $142,722,000 | $121,747,000 |
| Income Tax Paid Supplemental Data | $15,220,000 | $2,496,000 | $12,649,000 | $15,558,000 |
| End Cash Position | $118,420,000 | $99,107,000 | $35,227,000 | $256,739,000 |
| Beginning Cash Position | $99,107,000 | $35,227,000 | $256,739,000 | $347,121,000 |
| Effect Of Exchange Rate Changes | $-999,000 | $65,000 | $-5,683,000 | $102,000 |
| Changes In Cash | $20,312,000 | $63,815,000 | $-215,829,000 | $-90,484,000 |
| Proceeds From Stock Option Exercised | $1,154,000 | $451,000 | $662,000 | $853,000 |
| Net Issuance Payments Of Debt | $-185,118,000 | $22,652,000 | $-38,272,000 | $-79,179,000 |
| Net Short Term Debt Issuance | $48,000,000 | $219,000,000 | $85,000,000 | $0 |
| Short Term Debt Issuance | $48,000,000 | $219,000,000 | $85,000,000 | $0 |
| Net Long Term Debt Issuance | $-233,118,000 | $-196,348,000 | $-123,272,000 | $-79,179,000 |
| Long Term Debt Payments | $-233,118,000 | $-414,080,000 | $-123,272,000 | $-79,179,000 |
| Long Term Debt Issuance | $0 | $217,732,000 | $0 | $0 |
| Net Business Purchase And Sale | $11,994,000 | $0 | $-84,714,000 | $-146,543,000 |
| Sale Of Business | $11,994,000 | $0 | $0 | $0 |
| Purchase Of Business | $0 | $0 | $-84,714,000 | $-146,543,000 |
| Net Intangibles Purchase And Sale | $-14,650,000 | $-22,388,000 | $-41,800,000 | $-1,700,000 |
| Purchase Of Intangibles | $-14,650,000 | $-22,388,000 | $-41,800,000 | $-1,700,000 |
| Net PPE Purchase And Sale | $-60,340,000 | $-46,801,000 | $-48,795,000 | $-50,939,000 |
| Purchase Of PPE | $-60,340,000 | $-46,801,000 | $-48,795,000 | $-50,939,000 |
| Change In Working Capital | $-4,068,000 | $-47,186,000 | $-59,945,000 | $-133,593,000 |
| Change In Payables And Accrued Expense | $289,576,000 | $-84,617,000 | $111,640,000 | $-46,287,000 |
| Change In Payable | $289,576,000 | $-84,617,000 | $111,640,000 | $-46,287,000 |
| Change In Account Payable | $235,135,000 | $-94,446,000 | $109,568,000 | $-43,932,000 |
| Change In Prepaid Assets | $-959,000 | $37,814,000 | $9,882,000 | $-21,981,000 |
| Change In Inventory | $-130,530,000 | $-126,182,000 | $-102,396,000 | $-49,015,000 |
| Change In Receivables | $-162,155,000 | $125,799,000 | $-79,071,000 | $-16,310,000 |
| Changes In Account Receivables | $-162,637,000 | $126,289,000 | $-79,717,000 | $-23,621,000 |
| Other Non Cash Items | $4,415,000 | $44,413,000 | $17,445,000 | $15,188,000 |
| Stock Based Compensation | $27,768,000 | $26,822,000 | $31,847,000 | $28,412,000 |
| Provisionand Write Offof Assets | $96,558,000 | $74,686,000 | $51,096,000 | $54,660,000 |
| Asset Impairment Charge | $920,000 | $66,932,000 | $24,081,000 | $23,402,000 |
| Depreciation Amortization Depletion | $236,191,000 | $229,400,000 | $240,175,000 | $233,406,000 |
| Depreciation And Amortization | $236,191,000 | $229,400,000 | $240,175,000 | $233,406,000 |
| Net Foreign Currency Exchange Gain Loss | $7,191,000 | $-768,000 | $15,190,000 | $175,000 |
| Net Income From Continuing Operations | $-73,876,000 | $-48,722,000 | $-254,789,000 | $20,170,000 |
| Amortization Cash Flow | - | $163,200,000 | $172,063,000 | $172,700,000 |
| Amortization Of Intangibles | - | $163,200,000 | $172,063,000 | $172,700,000 |
| Depreciation | - | $66,200,000 | $68,112,000 | $60,700,000 |
| Gain Loss On Sale Of Business | - | - | $0 | $0 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $5,152,000 |